Appeal No. 2006-0624 Page 5
Application No. 10/096,127
and Enssle, or as obvious over the combination of Ashkenazi I or Ashkenazi II,
Novick, Levinson and Enssle. As the rejections are essentially the same, we
focus our analysis on the first combination of references. In addition, as the
claims stand or fall together, see Appeal Brief, page 3, we also focus our analysis
on claim 10.
Queen is cited for teaching that humanized anti-IFN gamma antibody may
be used to treat autoimmune diseases, although the examiner acknowledges that
the reference does not teach the treatment of psoriasis. See Examiner’s Answer,
page 3.
Ashkenazi I and Ashkenazi II are cited for teaching that IFN gamma is
involved in the pathogenesis of inflammatory bowel disease and that anti-IFN
gamma antibody may be used to treat inflammatory bowel disease, including
Crohn’s disease. See id. at 3-4. The Ashkenazi references are also cited for
teaching that IFN gamma is known to exacerbate autoimmune diseases such as
psoriasis. See id. at 4.9
Levinson is cited for teaching that TH1 cells secrete IFN gamma, and that
autoimmune diseases such as psoriasis and Crohn’s disease are TH1 related
disorders. See id.
Enssle is cited for teaching that SLE is a TH2 associated disease. See id.
at 5.
The rejection concludes:
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007